Clinical trials: Influenza H1N1
Healthy Volunteers
Characterization of the Innate Immune Response in Healthy NIH Employees at Baseline and After Immunization With the H1N1 Vaccine
Background: The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases is conducting research investigating how the swine flu (H1N1) vaccine affects the immune system.
- Trial name
- NCT00995527
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pandemic Influenza
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
This present study, randomized, single-blind, dose-ranging, multicenter study, will evaluate immunogenicity, safety and tolerability of two doses of an adjuvanted and not-adjuvanted new swine-origin influenza A/H1N1 virus…
- Trial name
- NCT00970177
- Testing
- Monovalent A/H1N1 influenza vaccine
- Where
- 3 sites in Belgium, Germany and 1 more
- Volunteers
- 812 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population
This is a laboratory-blinded study in healthy toddlers, children, and teenagers designed to investigate the safety, reactogenicity, and immunogenicity of an inactivated influenza H1N1 vaccine (AdimFlu-S).
- Trial name
- NCT01007201
- Testing
- Influenza A (H1N1) 2009 monovalent vaccine, inactivated
- Where
- 2 sites in Taiwan
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Influenza
2009 H1N1 Pandemic and Seasonal Influenza in SCI/D: Infection Control Strategies
The purpose of this study is to evaluate specific approaches used to prevent/reduce influenza transmission in the SCI/D System of Care in response to the 2009 H1N1 pandemic, including assessing infection control strategies used…
- Trial name
- NCT01270685
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Influenza
Safety and Immunogenicity Study of Fluval AB-Like Flu Vaccines With 3.5, 6, 9 or 15 μg HA in Adult and Elderly People
The purpose of this study is to determine the immunogenicity, tolerability and dose-effect relationship of one 0.5 mL intramuscular (IM) injection of four FLUVAL AB-like trivalent influenza vaccines containing either 3.5μgHA…
- Trial name
- NCT01408290
- Testing
- Vaccination with FAB-3511, Vaccination with FAB-6011, Vaccination with FAB-9011
- Where
- 4 sites in Hungary
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)
This trial will assess the immunogenicity and safety elicited by the adjuvanted GSK Biologicals' influenza investigational vaccine GSK2340274A in healthy Japanese adults aged 20-64 years.
- Trial name
- NCT00989612
- Testing
- Influenza investigational vaccine GSK2340274A
- Where
- 2 sites in Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pandemic Influenza
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
This present study, randomized, single-blind, dose-ranging, multicenter study, will evaluate immunogenicity, safety and tolerability of two doses of an adjuvanted and not-adjuvanted new swine-origin influenza A/H1N1 virus…
- Trial name
- NCT00971906
- Testing
- Monovalent A/H1N1 influenza vaccine
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza A Virus, H1N1 Subtype
A Pragmatic Randomized Controlled Trial of Chinese Herbal Medicine for Severe Pandemic H1N1 Influenza
The aim of this study is to evaluate the effectiveness and safety of Chinese herbal medicines for severe pandemic H1N1 influenza.
- Trial name
- 200907001-2A (NCT01053533)
- Testing
- Chinese herbal medicines plus western therapy, western therapy
- Where
- China
- Volunteers
- 1,100 people
- Sponsor
- Beijing Ditan Hospital
Influenza
Evaluation of Pandemic Influenza A (H1N1)Candidate Vaccines
This is a prospective phase I study to evaluate the safety, tolerability and immunogenicity of nine adjuvanted candidate vaccines against pandemic influenza A (H1N1) virus.
- Trial name
- NCT01111968
- Testing
- pandemic vaccine 1, pandemic vaccine 2, pandemic vaccine 5
- Where
- 2 sites in Brazil
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Cystic Fibrosis With Gastrointestinal Manifestation
Cohort Study Evaluating the Clinical Effectiveness, Safety and Immunogenicity to the Pandemic Influenza Vaccination
Multicenter prospective cohort of approximately 1000 cystic fibrosis patients followed in the Ile de France during the 2009-2010 influenza season with the main objective to assess the effectiveness of antiviral vaccination…
- Trial name
- MUCOFLU (NCT01499914)
- Testing
- influenza vaccination
- Where
- France
- Volunteers
- 439 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Seasonal Influenza
Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children
The seasonal influenza vaccination program for 2010-2011 will be the first to follow the H1N1 pandemic of 2009. Many children either had the H1N1 infection or the adjuvanted H1N1 vaccine.
- Trial name
- NCT01180621
- Testing
- Fluviral
- Where
- 4 sites in Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Dalhousie University
Influenza
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.
- Trial name
- NCT00968539
- Testing
- GSK investigational vaccine GSK2340272A, GSK investigational vaccine GSK2340269A
- Where
- Belgium
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children
The purpose of this study is to assess the safety and immunogenicity of two doses of the H1N1 candidate vaccine administered in children aged between 8 and 12 weeks at the time of first vaccination.
- Trial name
- NCT01003418
- Testing
- GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine, Infanrix™-IPV/Hib, Prevenar
- Where
- 4 sites in Norway
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Novartis H1N1 Vaccine in Pregnant Women
The purpose of this study is to evaluate the safety of a 2009 H1N1 influenza vaccine in pregnant women and to determine how their body reacts to different strengths of the vaccine.
- Trial name
- NCT00992719
- Testing
- Inactivated H1N1 Vaccine
- Where
- 6 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults
This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 18 to 64 years of age.
- Trial name
- NCT01008956
- Testing
- GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Rheumatic Diseases
Vaccination Against Influenza H1N1 in Rheumatic Diseases
The spread of Influenza H1N1 has prompted the development of vaccines against this virus. Immunocompromised patients are at increased risk of developing complications of Influenza H1N1.
- Trial name
- NCT01006681
- Testing
- Focetria (Monovalent MF59-Adjuvanted vaccine)
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Pneumonia, Viral, Influenza in Humans
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
The H1N1 flu pandemic is one of the major infectious threat of the past half century. it is rapidly progressing worldwide and a substantial number of patients get severe H1N1 related pneumonia that requires mechanical ventilation…
- Trial name
- CORTIFLU (NCT01014364)
- Testing
- hydrocortisone, isotonic saline
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University of Versailles
Influenza, Human
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
People who are infected with the influenza virus may develop respiratory illnesses, such as pneumonia, or other life-threatening complications. Currently, there are four antiviral medications that are used to treat influenza.
- Trial name
- NCT01314911
- Testing
- Oseltamivir
- Where
- 51 sites in United States, Argentina and 1 more
- Volunteers
- 716 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immunocompromised Patients, Safety of Pandemic Influenza A (H1N1)Vaccine
Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants
The objective of this study is to describe the safety and immunogenicity of a non-adjuvanted vaccine against pandemic influenza A (H1N1)in patients with chronic and or immunocompromised disease, elderly and pregnants.
- Conditions
- Immunocompromised Patients, Safety of Pandemic Influenza A (H1N1)Vaccine, Immunogenicity of Pandemic Influenza A (H1N1)Vaccine
- Trial name
- NCT01218685
- Testing
- Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS
- Where
- Brazil
- Volunteers
- 1,152 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
H1N1 Influenza
Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation
Stem cell and and heart transplant patients will receive pandemic H1N1 influenza vaccination according to the clinical guidelines. In these patients the investigators will measure the specific antibody production.
- Trial name
- NCT01008683
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Hadassah Medical Organization